Uitentuis SE, et al. - In a population-based setting, researchers characterized the incidence, treatment, and survival of Merkel cell carcinoma (MCC). Between 1993 and 2016, all MCCs diagnosed in The Netherlands were chosen from the Netherlands Cancer Registry. The study sample consisted of 1977 patients with MCC. According to results, incidence rose from 0.17 per 100,000 person-years in 1993 to 0.59 per 100,000 in 2016. Most MCCs have been treated with surgery alone. Findings revealed that mortality was higher among males, higher age, and nodal and distant spread of disease. This research demonstrates the incidence rates of MCC in the Netherlands continually rising. Survival stayed low after an MCC diagnosis. The findings highlight the need for new therapies to be implemented.